Biond develops first in class antibodies that can successfully fight and destroy the immune-escape mechanisms of cancer cells. Biond’s in-house pipeline is based on research of less-charted waters in the fields of immune-checkpoints and immune-evasion and aim to fill the gaps created by current cancer therapies (such as non-responders, drug-resistance, etc.) and improve the outcome of cancer patients to immunotherapies.
BION-202 – an innovative immunotherapy drug candidate which generates an anti-tumor immune response by blocking the activity of a receptor expressed by both myeloid cells and lymphocytes that binds to a yet untargeted well-known tumor antigen.
BION-203 – an innovative immunotherapy drug candidate which generates an anti-tumor immune response by blocking a protein with a key role in the activity of suppressive myeloid cells, which are known to generate a highly suppressive tumor microenvironment that limits the potency of cancer therapies.
BION-206 – an immunotherapy drug candidate which intensifies anti-tumor T cell activity by targeting a highly central immune pathway using a novel approach.